Actelion’s mission is to treat more patients with groundbreaking therapies. With our portfolio of innovative medicines, we are serving increasing numbers of patients in countries throughout the world. At the end of 2016, over 70,000 patients were benefiting from Actelion’s drugs. We are leaders in the science and treatment of pulmonary arterial hypertension (PAH), with over 15 years’ experience in this area. Our understanding of the complex pathways and molecular mechanisms of this disease has enabled the development of tailored medicines that can make a real difference to patient outcomes.


Patient organizations can be an important support network and source of information for patients who are living with illnesses. They are non-profit organizations that help to raise awareness of treatment options and advocate for better patient care.

Actelion believes that patient organizations should be independent, and we abide by the relevant codes of practice for interacting with patient organizations.


Actelion has either provided grants or given donations to the following patient organizations: